Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05129865 | LYT-300 in Healthy Volunteers | PHASE1/PHASE2 | COMPLETED | 186 | — | — | Dec 1, 2021 | Oct 1, 2023 | Nov 12, 2023 | - | — |
| Name | Type | Description |
|---|---|---|
| LYT-300 | DRUG | A prodrug of allopregnanolone, a small molecule drug |
| Placebo | OTHER | Placebo for LYT-300 |